External resources SURMOUNT-5 Trial: Tirzepatide vs Semaglutide for Obesity (New England Journal of Medicine) SURPASS-2 Trial: Tirzepatide vs Semaglutide for Type 2 Diabetes (New England Journal of Medicine) Tirzepatide Dual GIP/GLP-1 Receptor Agonist Mechanism (JCI Insight) Why Weight Loss Drugs Do Not Work for Everyone: Genetics (Scientific American) Factors Associated with Weight Loss Response to GLP-1 Analogues (PMC) In case I do not see you, good afternoon, good evening, and good night
Brazil nuts, sardines, and grass-fed beef are excellent sources
The overall market for the kinds of treatments employed in these medicationswhich are known as GLP-1s and are also used to treat Type 2 diabetesis seen as even larger, at some $168 billion
Ohta A, Kato H, Ishii S et al (2017) Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
If not applied correctly or excessively, improper usage can lead to minor adverse effects, thus an understanding of precautions is quite important when adding it to the routine